Sintx Technologies, Inc. (SINT)

NASDAQ: SINT · Real-Time Price · USD
2.480
+0.130 (5.53%)
May 11, 2026, 4:00 PM EDT - Market closed
Market Cap10.22M +57.3%
Revenue (ttm)1.02M -64.7%
Net Income-17.08M
EPS-6.16
Shares Out 4.12M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume33,975
Open2.320
Previous Close2.350
Day's Range2.320 - 2.480
52-Week Range1.990 - 6.780
Beta0.61
AnalystsStrong Buy
Price Target11.00 (+343.55%)
Earnings DateMay 13, 2026

About SINT

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. The company offers monolithic solid silicon nitride; solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyether ether ketone, and Polyether Ether Ketone (PEE). The company was formerly known as Amedica Cor... [Read more]

Sector Healthcare
IPO Date Feb 13, 2014
Employees 32
Stock Exchange NASDAQ
Ticker Symbol SINT
Full Company Profile

Financial Performance

In 2025, Sintx Technologies's revenue was $1.02 million, a decrease of -64.74% compared to the previous year's $2.89 million. Losses were -$17.08 million, 55.0% more than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for SINT stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 343.55% from the latest price.

Price Target
$11.0
(343.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sintx Technologies initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Sintx Technologies (SINT) with a Buy rating and $10 price target Sintx is developing silicon nitride-based biomaterials, which offer a “differentiated combination...

4 weeks ago - TheFly

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026

7 weeks ago - GlobeNewsWire

Sintx Technologies announces first in-human surgery using FDA-cleared Sinaptic

The company states: “SINTX Technologies (SINT) announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, mark...

7 weeks ago - TheFly

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform

7 weeks ago - GlobeNewsWire

Sintx Technologies appoints Elmore as President

Sintx Technologies (SINT) announced the appointment of Ryan Elmore as President of SINTX Technologies, effective March 16, 2026. Elmore most recently served as Core Business Director at Invibio, a div...

2 months ago - TheFly

SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

Appointment supports acceleration of revenue opportunities from SiNERGY ™ silicon nitride devices and antipathogenic fibrous material technologies

2 months ago - GlobeNewsWire

SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-bas...

3 months ago - GlobeNewsWire

Sintx Technologies signs supply agreement with EVONIK

SINTX Technologies (SINT) signed a supply agreement with Evonik to manufacture the Company’s proprietary silicon nitride-PEEK compound engineered for AI-assisted additive manufacturing of patient-spec...

5 months ago - TheFly

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advance...

5 months ago - GlobeNewsWire

Sintx Technologies reports Q3 EPS ($3.46) vs ($6.96) last year

Reports Q3 revenue $208k vs $799k last year. “We have aligned SINTX squarely behind near-term commercial milestones with our advanced biomaterial products,” said Eric Olson, President and CEO of SINTX...

6 months ago - TheFly

Sintx Technologies announces launch of OsseoSculpt

SINTX Technologies (SINT) announced the execution of a private label agreement to supply OsseoSculpt, a next-generation biologic designed to complement the Company’s FDA 510(K) cleared SINAPTIC Foot &...

6 months ago - TheFly

SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System

Clinical evaluation of the product by design surgeons completed, driving early commercial momentum SALT LAKE CITY, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SIN...

6 months ago - GlobeNewsWire

Sintx Technologies files to sell 1.74M shares of common stock for holders

The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling stockholders of the shares. Published…

7 months ago - TheFly

Sintx receives FDA clearance for SINAPTIC Foot, Ankle implant system

SINTX Technologies (SINT) announced U.S. Food and Drug Administration, FDA, 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive...

7 months ago - TheFly

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

FDA cleared and U.S. manufactured implant system positions SINTX to enter billion-dollar U.S. market SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“S...

7 months ago - GlobeNewsWire

Sintx Technologies announces U.S. patent notice of allowance

SINTX Technologies (SINT) announced that the United States Patent and Trademark Office issued a Notice of Allowance for a patent application containing method claims covering the Company’s antipathoge...

7 months ago - TheFly

SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics

New method patent expands SINTX's infection-prevention IP portfolio in $30 Billion Total Addressable Market U.S. Patent Notice of Allowance reinforces competitive advantage and enables broader licensi...

7 months ago - GlobeNewsWire

Sintx Technologies files to sell 541,450 shares of common stock for holders

16:54 EDT Sintx Technologies (SINT) files to sell 541,450 shares of common stock for holders

7 months ago - TheFly

Why Is Sintx Technologies Stock (SINT) Down 20% Today?

Sintx Technologies stock was down on Monday after the company announced a warrant exercise agreement.

8 months ago - TipRanks

Sintx Technologies announces exercise of warrants for $3.8M gross proceeds

SINTX Technologies (SINT) announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,099,431 shares of common stock o...

8 months ago - TheFly

SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds

SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of s...

8 months ago - GlobeNewsWire

Sintx Technologies receives USPTO notice of allowance

SINTX Technologies (SINT) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application titled, “Antipathogenic Fibrous Materials.” The paten...

8 months ago - TheFly

SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent

Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the...

8 months ago - GlobeNewsWire

Sintx Technologies publishes study of antiviral activity of Silicon Nitride

SINTX Technologies (SINT) announced the publication of a peer-reviewed study demonstrating that silicon nitride exhibits potent antiviral activity against multiple infectious virus strains, including ...

8 months ago - TheFly

Sintx Technologies issues business update following strategic realignment

SINTX Technologies (SINT) issued a business update in connection with the filing of the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the…

9 months ago - TheFly